Browsing by Author Sommeijer, Dirkje

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2013Hormonal Treatment in Recurrent and Metastatic Gynaecological Cancers: A Review of the Current LiteratureFriedlander, Michael; Sjoquist, Katrin; Sommeijer, Dirkje; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreHormonal Treatment in Recurrent and Metastatic Gynaecological Cancers: A Review of the Current Literature, Current Oncology, vol.15, 6, 2013,pp 541-548
2013Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of lifeBell, Melanie; Butow, Phyllis; deFazio, Anna; Friedlander, Michael; Price, Melanie; Sommeijer, Dirkje; Stockler, Martin; Webb, Penelope M.; Psychology; Psychology; Western Clinical School: Westmead Millennium Institute; School of Public Health: NH&MRC Clinical Trials Centre; Psychology; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentrePhysical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life, Gynecologic Oncology, vol.130, 1, 2013,pp 162-168
2014The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17Simes, Robert John; Sommeijer, Dirkje; Jonker, Derek J.; Karapetis, Christos; O’CALLAGHAN, Chris; Price, Timothy; Tebbutt, Niall; Tu, Dongsheng; Yip, Desmond; Zalcberg, John; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreThe relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17, Acta Oncologica, vol.53, 7, 2014,pp 877-884